234 related articles for article (PubMed ID: 27068257)
21. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P
Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.
Pérez-Molina JA; Martínez E; Blasco AJ; Arribas JR; Domingo P; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Mariño A; Miró JM; Moreno S; Negredo E; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; von Wichmann MA; Gatell JM
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):151-159. PubMed ID: 29884455
[TBL] [Abstract][Full Text] [Related]
24. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
25. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.
Ribera E; Martínez-Sesmero JM; Sánchez-Rubio J; Rubio R; Pasquau J; Poveda JL; Pérez-Mitru A; Roldán C; Hernández-Novoa B
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Mar; 36(3):157-164. PubMed ID: 28109551
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.
Günthard HF; Saag MS; Benson CA; del Rio C; Eron JJ; Gallant JE; Hoy JF; Mugavero MJ; Sax PE; Thompson MA; Gandhi RT; Landovitz RJ; Smith DM; Jacobsen DM; Volberding PA
JAMA; 2016 Jul; 316(2):191-210. PubMed ID: 27404187
[TBL] [Abstract][Full Text] [Related]
27. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
29. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
[TBL] [Abstract][Full Text] [Related]
30. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
31. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
32. [Consensus statement on assistance to women with human immunodeficiency virus infection in the health care sector. National AIDS Plan (PNS) and AIDS Study Group (GeSIDA)].
;
Enferm Infecc Microbiol Clin; 2014 Feb; 32(2):99.e1-99.e14. PubMed ID: 23896395
[TBL] [Abstract][Full Text] [Related]
33. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
Thompson MA; Aberg JA; Hoy JF; Telenti A; Benson C; Cahn P; Eron JJ; Günthard HF; Hammer SM; Reiss P; Richman DD; Rizzardini G; Thomas DL; Jacobsen DM; Volberding PA
JAMA; 2012 Jul; 308(4):387-402. PubMed ID: 22820792
[TBL] [Abstract][Full Text] [Related]
34. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
Hammer SM; Eron JJ; Reiss P; Schooley RT; Thompson MA; Walmsley S; Cahn P; Fischl MA; Gatell JM; Hirsch MS; Jacobsen DM; Montaner JS; Richman DD; Yeni PG; Volberding PA;
JAMA; 2008 Aug; 300(5):555-70. PubMed ID: 18677028
[TBL] [Abstract][Full Text] [Related]
36. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
38. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys EH; Chang LW; Harris J
Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
[TBL] [Abstract][Full Text] [Related]
40. [Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)].
Viciana P; Ocampo A; Hevia H; Palazuelos M; Ledesma F
Enferm Infecc Microbiol Clin; 2014 Feb; 32(2):93-5. PubMed ID: 24144784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
